AstraZeneca | Investor Day Presentation Deck | 35 slides

AstraZeneca · 2022-02
arc beats above · slides in the middle · loops below · scroll → 0 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

35
every slide · same image gating as the playbook
01
Slide 1
Includes company logo and date.front_matter
03
introduce_nominees
04
front_matter
05
Slide 1 of a presentation deck.front_matter
06
The diagram uses a circular flow to categorize drug mechanisms (Immune engagers, Cell therapy, Oncolytic virus, Immuno-oncology, DNA damage response, Antibody dpresent_framework
Open slide detailBeat · Interest
07
The slide categorizes the 19 abstracts into oral, mini-oral, and poster presentations, and lists three specific clinical trial highlights.summarize
Open slide detailBeat · Interest
08
The slide combines a Kaplan-Meier survival curve with a biological process flow diagram to support the clinical efficacy findings.analyze_data
09
transition
10
The slide uses a standard clinical trial flow diagram (CONSORT-style).present_framework
11
The slide demonstrates that the two study arms are well-balanced at baseline, which is a standard requirement for clinical trial validity.analyze_data
12
Clinical trial data presentation; includes hazard ratio and median rPFS comparison.analyze_data
13
The slide uses a Kaplan-Meier plot to visualize time-to-event data for a clinical trial.analyze_data
14
The slide uses a forest plot to visualize HRs and 95% CIs for multiple clinical subgroups.analyze_data
15
Clinical trial data presentation (Kaplan-Meier plot).analyze_data
16
Clinical trial data showing hazard ratios and median survival times for secondary endpoints.analyze_data
17
The slide highlights specific safety metrics including AE grades, death, and treatment modifications.analyze_data
18
SMQ = Standardised MedDRA Query; CT = computerised tomography.analyze_data
19
The chart uses a diverging bar structure to compare two treatment arms.analyze_data
20
The slide uses color-coded text (orange) to emphasize key clinical findings.summarize
21
The slide features a stylized silhouette of a human figure with internal biological/molecular imagery.transition
Open slide detailBeat · Problem (Identify pain)
22
The slide uses a matrix-like structure to segment patients by disease stage (Hormone sensitive vs Castration resistant) and prior treatment exposure (NHA naive diagnose_problem
Open slide detailBeat · Problem (Identify pain)
23
The slide uses a three-column layout to frame the problem (left), the study design (middle), and the clinical outcomes (right).summarize
Open slide detailBeat · Agitate (Make it worse)
24
The slide uses a patient image to humanize the clinical data. The comparison focuses on the delta (8.2m) between control/standard and experimental arms.compare_peers
Open slide detailBeat · Solution (Provide relief)
25
The slide uses a flow-chart style diagram to segment the patient population and position the Lynparza + abiraterone combination.present_solution
Open slide detailBeat · Solution (Provide relief)
26
Slide 4 of the presentation deck.transition
27
The slide presents two distinct clinical data sets: a summary table for the BAYOU trial and a spider plot for the U105 trial.analyze_data
28
The slide features a stylized silhouette of a human head and torso with biological/molecular imagery inside.state_next_steps
31
transition
32
Includes a Kaplan-Meier curve for rPFS and a forest plot for HR by HRRm subgroup.analyze_data
33
Data presented as stacked bar charts showing CR, PR, SD, and PD components.analyze_data
34
The chart shows overlapping confidence intervals, supporting the conclusion of comparability.analyze_data